SCHEMBL2220752

SCHEMBL2220752

O=C1CCCc2[nH]c3ccccc3c21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
HSD17B10 Q99714 2/20 0.57
KDM4E B2RXH2 5/20 0.56
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 3/20 0.44
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
PARP1 P09874 6/20 0.43
MAPT P10636 1/20 0.43
CHEK1 O14757 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
TNKS2 Q9H2K2 2/20 0.41
PARP2 Q9UGN5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31027151 1.00 DYRK1A (0.58) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL7441456 0.96 KDM4E (0.60) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL4287798 0.89 KDM4E (0.50) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL30451928 0.89 KDM4E (0.50) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL23537356 0.82 PARP1 (0.59) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL29824193 0.82 PARP1 (0.59) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL29824409 0.79 PARP1 (0.64) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL8455896 0.79 KDM4E (0.47) MEN1KMT2AHSD17B10KDM4EALDH1A1
SCHEMBL23537328 0.79 PARP1 (0.64) DYRK1AMEN1KMT2AHSD17B10KDM4E
SCHEMBL619090 0.78 KDR (0.60) MEN1KMT2AHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107235891-B Preparation method of 4-bromocarbazole 北京八亿时空液晶科技股份有限公司 2020-02-21 CN claimed
EP-1756057-B1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LTD (IN) 2010-08-04 EP claimed
US-7705163-B2 Process for the preparation of carvedilol CIPLA LIMITED (IN) 2010-04-27 US claimed
US-20080234492-A1 Process for the Preparation of Carvedilol CIPLA LIMITED (IN) 2008-09-25 US claimed
EP-1756057-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL Cipla Ltd. (IN) 2007-02-28 EP claimed
US-6977304-B2 Method for producing indoles MERCK PATENT GMBH (DE) 2005-12-20 US claimed
WO-2005113502-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LIMITED (IN) 2005-12-01 WO claimed
EP-0023592-B1 PROCESS FOR PREPARING 4-HYDROXYCARBAZOLE Roche Diagnostics GmbH (DE) 1983-03-30 EP claimed
US-4273711-A Process for the preparation of 4-hydroxycarbazole BOEHRINGER MANNHEIM GMBH (DE) 1981-06-16 US claimed
EP-0023592-A1 Process for preparing 4-hydroxycarbazole Roche Diagnostics GmbH (DE) 1981-02-11 EP claimed
US-20250381198-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2025-12-18 US disclosed
US-12350242-B2 Binge behavior regulators Clearmind Medicine Inc. (CA) 2025-07-08 US disclosed
WO-2025110008-A1 CURABLE COMPOSITION, METHOD FOR PRODUCING PIXEL, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND PHOTOPOLYMERIZATION INITIATOR 富士フイルム株式会社 2025-05-30 WO disclosed
WO-2025094724-A1 CURABLE COMPOSITION, METHOD FOR PRODUCING PIXEL, FILM, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, AND PHOTOPOLYMERIZATION INITIATOR 富士フイルム株式会社 2025-05-08 WO disclosed
US-20250066667-A1 Nonlinear Optical Chromophores Having Tetrahydrocarbazole Donor Groups, Lyotropic Compositions Containing the Same, and Methods of Poling Such Compositions LIGHTWAVE LOGIC, INC. (US) 2025-02-27 US disclosed
US-4273711-A Process for the preparation of 4-hydroxycarbazole BOEHRINGER MANNHEIM GMBH (DE) 1981-06-16 US disclosed
EP-0023592-A1 Process for preparing 4-hydroxycarbazole Roche Diagnostics GmbH (DE) 1981-02-11 EP disclosed
EP-0023592-A1 Process for preparing 4-hydroxycarbazole Roche Diagnostics GmbH (DE) 1981-02-11 EP disclosed
US-3892766-A Process for the preparation of 4-keto-1,2,3,4-tetrahydrocarbazole WARNER LAMBERT CO 1975-07-01 US disclosed
US-3892766-A Process for the preparation of 4-keto-1,2,3,4-tetrahydrocarbazole WARNER LAMBERT CO 1975-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12350242-B2 Binge behavior regulators GABRB3, GABRB2, GABRB1 DYRK1A 2022/4885MEN1 4592/4885KMT2A 501/4885
US-20250381198-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION KCNA3, OPRK1, KCNA7 DYRK1A 4470/4885MEN1 3968/4885KMT2A 489/4885
US-20080234492-A1 Process for the Preparation of Carvedilol ADRB2, ADRB3, ADRB1 DYRK1A 1066/4885MEN1 4640/4885KMT2A 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.